ODAC Sides With FDA: Evidence For Elderly AML Drugs Can't Stand On Single-Arm Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Feasible or not, randomized controlled trials are needed before approval of Genzyme's Clolar and Vion's Onrigin to treat elderly acute myeloid leukemia patients.